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A missed diagnosis. A missed opportunity for 
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The quality of life of people with learning disability and epilepsy, in the community, can be improved by 
regular eview and appropriate use of anti-convulsants. This paper eports two successful outcomes using a 
newer anti-convulsant, lamotrigine. 
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Epilepsy is a common condition in people with 
learning disability (LD), the risk of suffering 
from epilepsy increases with the severity of the 
LD 1 and some syndromes have LD and epilepsy 
as an integral part (e.g. Lennox-Gastaut). 
Point prevalence studies have revealed epi- 
lepsy rates of 40-50% in those with severe 
LD 1. 
Historically the management of epilepsy in 
this group of people was the domain of the LD 
psychiatrist in his role as medical superintend- 
ent of the hospital 1. Often these practitioners 
had no specialist raining in epilepsy and this 
may have led to inappropriate management. 
With the closure of the large institutions and 
the move into the community the general prac- 
titioner manages epilepsy. With regard to psy- 
chotropic medication, such reviews are often 
conservative and clients continue on the same 
medication they were taking on discharge 
(pers. comm. B. Louis). Probably the same is 
true of a.nticonvulsants. However, the general 
practitioner has the choice of referring to a 
neurologist or psychiatrist in LD for advice on 
the management of epilepsy. Opinions vary on 
which speciality serves this population 
better 2,3. 
At the same time as the closure of the mental 
handicap hospitals there have been the intro- 
duction of newer anticonvulsants as add-on 
therapy in treatment-resistant epilepsy, such 
as vigabatrin, lamotrigine and gabapentin. 
These drugs have different modes of action and 
side-effect profiles and are currently licensed 
as add-on treatments. Many of the LD popu- 
lation have poorly controlled epilepsy and thus 
would be candidates for these new anticonvul- 
sants 4, 5. 
We report two cases of poorly controlled epi- 
lepsy in people with LD, discharged into the 
community from a large hospital, on two anti- 
convulsants, in whom addition of lamotrigine 
was successful. 
CASE1 
BH is a 61-year-old lady with a mild learning 
disability of unknown aetiology. She lives with 
two other ladies in a staffed house in the com- 
munity, following her discharge from a mental 
handicap hospital 5 years previously. She was 
referred to the LD psychiatrist because of %e- 
haviour problems'. These problem behaviours 
had been occurring for at least 16 years and 
consisted of intermittent episodes where she 
became mute, apathetic, withdrawn and 
refused to eat and drink. There was evidence of 
psychomotor retardation. Her eyelids flickered 
and she took up bizarre postures, for example 
crucifix. During these episodes he was doubly 
incontinent. These episodes lasted from 2 
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hours to 4 days and on average occurred 4-6 
times a month, most often at weekends. 
At the age of 9 she was diagnosed as suffer- 
ing from epilepsy (tonic-clonic and absence 
seizures) and was commenced on primidone 
and phenytoin. An EEG performed when she 
was 48 revealed multifocal discharges with 
photosensitivity. The primidone and phenytoin 
were replaced by sodium valproate and carba- 
mazepine. At this time she suffered 2-4 tonic- 
clonic seizures per year and was also diagnosed 
and treated for hypothyroidism. 
Aged 52 she suffered carbamazepine toxicity 
and the dosage was reduced. At 60 years her 
general practitioner commenced Sinemet 110 
after making a clinical diagnosis of Parkin- 
son's disease. 
A clinical diagnosis of non-convulsive gener- 
alized status epilepticus was made. An EEG 
confirmed the potential for a seizure disorder 
probably both multifocal and primary general- 
ized. Blood tests including thyroid function 
tests were all within normal limits. 
Lamotrigine was introduced initially at 
25 mg nocte and gradually increased to 100 mg 
twice daily. Over a period of 4 months the car- 
bamazepine was reduced and stopped and the 
sodium valproate continued at 500mg twice 
daily with the intention of reducing the dosage 
at a later date. 
There was a reduction in frequency and 
duration of the withdrawn, mute episodes and 
at 4 months after commencing lamotrigine 
there were no further episodes. 
A further increase in the lamotrigine dosage 
to 200 mg twice daily led to complaints by the 
patient of unsteadiness, dizziness and nausea. 
On examination she was ataxic and showed 
signs of cerebellar dysfunction. Reduction of 
the lamotrigine to 150 mg nocte produced a res- 
olution of these symptoms. In the following six 
months there has only been one brief with- 
drawn episode. 
CASE2 
J J  is a 29-year-old man with severe learning 
disability with cerebral palsy, quadriplegic, 
with no speech and completely dependent on 
carers. He was referred to the Learning Dis- 
ability Service as his tonic-clonic seizure fre- 
quency was steadily increasing following his 
resettlement in a community home a year ago 
from a large mental handicap hospital. At the 
time of first assessment, J J  was drowsy, droop- 
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ing on his wheelchair with little response to 
verbal commands. He was on sodium valproate 
800 mg bd and phenytoin 125 mg and 100 mg 
daily, together with other medications for con- 
stipation. There were no old medical files avail- 
able, thus the type of epilepsy and investi- 
gations were unknown. 
With gradual reduction in sodium valproate 
and the introduction of lamotrigine, there was 
a dramatic improvement in his general well- 
being. He became more alert, happy, smiling, 
responding to his name by turning his head, 
his appetite also improved and the physio- 
therapist reported that the motor power in his 
limbs started improving. 
Seizure frequency was minimal three 
months after the start of lamotrigine, but there 
was a slight increase in frequency following 
the cessation of sodium valproate after five 
months. However post-ictal recovery is more 
rapid. His general well-being continues to im- 
prove, and it was certainly a rewarding experi- 
ence for his carers and parents who visit him 
regularly. 
DISCUSSION 
Lamotrigine was introduced into the UK in 
1991. It is a triazine compound which acts by 
inhibiting glutamate release by blocking 
sodium channels 6. Its protein binding is 
around 55%. It is metabolized in the liver, 
largely by glucuorinadation and half life is 25-  
30 hours v. 
It is licensed in the UK as add-on treatment 
of partial seizures and secondarily generalized 
tonic-clonic seizures not satisfactorily con- 
trolled with other anti-epileptic drugs. 
Recently the drug has been licensed for use in 
children over two years of age s . It may also be 
effective in other types of epilepsy, including 
absence, myoclonic, tonic, clonic and tonic-clo- 
nic seizures 7 and perhaps in Lennox-Gastaut 
Syndrome 9.
Side-effects of lamotrigine are small, 
although higher doses can cause headache, diz- 
ziness, diplopia, drowsiness, nausea and vomit- 
ing which usually resolve on reduction of 
dosage. A maculopapular rash is seen in 3% of 
patients which may lead to withdrawal of the 
drug 7. This appears hortly after the introduc- 
tion of the drug. A slow introduction of lamotri- 
gine reduces the incidence of rash 4. 
The main drug interaction is with sodium 
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valproate which inhibits the metabolism of 
lamotrigine hence increasing its half-life to 60 
hours 5, thus lamotrigine toxicity may occur at 
a lower dose as illustrated in Case 1. 
Non-convulsive status epilepticus (NCSE) 
makes up at least a quarter of all status epilep- 
ticus l°. Symptoms include continuous state of 
altered consciousness, rhythmic shaking, 
clonic twitching, automatisms and myoclonic 
jerking of the limbs or face. Speech is also 
reduced 11. Ictal phenomena may suggest he 
presence of a psychiatric illness 12. 
Thus misdiagnosis of non-convulsive status 
epilepticus i  not uncommon. In the first case 
this had led to the carers perceiving the person 
in a negative light. It had also led to a late 
presentation to the service. 
The cases highlight the need for regular 
review of people with epilepsy and learning dis- 
ability. This is to ensure optimal treatment in
the context of innovations in epilepsy manage- 
ment. There is a risk of therapeutic nihilism in 
the management of people with epilepsy and 
learning disability. Inappropriate use of 
certain anticonvulsants may also impair cogni- 
tion and therefore further handicap the person. 
In order to improve the quality of life of an 
individual with LD and epilepsy, regular and 
continuing assessment is required of the risks 
and benefits of anticonvulsant medication. 
Both the cases howed positive changes in qual- 
ity of life with the improvement in their seizure 
management. 
The mood stabilizing effects of carbamaze- 
pine and sodium valproate are widely known 
and lamotrigine has been reported anecdotally, 
to improve well-being. This might have had an 
effect in our  cases  13. It is not known if this is a 
result of improved seizure control or of other 
unknown mechanisms. 
These two cases reveal the utility of lamotri- 
gine in people with intratractable epilepsy and 
learning disability. 
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